The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
NCT ID: NCT06837298
Last Updated: 2025-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
76 participants
INTERVENTIONAL
2025-02-07
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vegan or Animal Protein Ingestion on the Recovery of Muscle Function Following Exercise
NCT04156386
Exploring Muscle Breakdown During Exercise Recovery
NCT04841772
Protein and Recovery From Exercise-induced Muscle Damage
NCT02034721
Vegan Whey Protein for Muscle Anabolism and Post-exercise Recovery
NCT07119749
Effects of Pea Proteins on Muscle Damage and Recovery
NCT05657314
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A recent study (Kerr, et al., 2023) investigated the effects of a protein supplement (PeptiStrong®) from Vicia faba protein concentrate, a protein derived from Fava bean extract. Results showed that 17 days of 2.4 grams of PeptiStrong® significantly improved muscle strength, reduced muscle fatigue, and reduced myostatin expression during the 72 hour recovery period compared to placebo following a strenuous bout of eccentric exercise. This study aims to repeat the methods of Kerr, et al. with the addition of females and a third experimental group. In addition to 17 days of supplementation with Vicia faba Hydrolysate or placebo, a third group will be given 14 days of placebo followed by 3 days of the Vicia faba Hydrolysate supplement to determine if short-term supplementation results in a similar benefit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
PeptiStrong® capsules 2.4 grams per day for 17 days
Placebo control capsules
2.4 grams (g) daily
PeptiStrong® 17 days
PeptiStrong® capsules 2.4 grams/day for 17 days
PeptiStrong® supplement capsules with same appearance as placebo capsules
2.4 g daily
PeptiStrong® 3 days
14 days of Placebo followed by 3 days of PeptiStrong®
PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo control capsules
2.4 grams (g) daily
PeptiStrong® supplement capsules with same appearance as placebo capsules
2.4 g daily
PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to fast overnight on the 4 testing occasions.
* Participants agree to abstain from taking additional supplements throughout the testing period, with particular emphasis placed upon protein-based products (e.g., whey or casein based protein powders; animal derived protein hydrolysates; natural supplements constituted of vegetative protein hydrolysates from rice, fava bean, pea, carrot, spirulina, broccoli, potatoes; marine derived secondary metabolite products or protein hydrolysates including Omega-3 capsules or DHA).
* Moderately active (exercise 3-5 days per week)
* Fluent in reading, writing, and speaking English
* Participants agree to maintain their normal diet and perform only light to moderate exercise for the duration of the study.
* BMI between 18.5 and 29.9 kg/m2
* Participants agree to refrain from consuming alcohol in the 48 hours leading up to a test day.
* Willingness to complete questionnaires, records and diaries associated with the study and to complete all lab visits.
* Refrain from any exercise from 48 hours prior to each test or blood draw.
* Healthy as determined by General Health Questionnaire.
* Non-smoker
Exclusion Criteria
* Alcohol or drug abuse in the past year.3. Testosterone or estrogen supplementation (not including women on oral contraceptives)
* Pregnant or nursing or planning to become pregnant.
* Participation in any other clinical trial in the past 30 days. Participation in any PepsiCo trial in the past 6 months
* Volunteers with unstable medical conditions.
* Any complaints that could interfere with the ability to exercise.
* Individuals who are cognitively impaired or unable to give informed consent.
* Any co-morbidities interacting with mobility or muscle metabolism of the lower limbs (e.g. arthritis, spasticity / rigidity, all neurological disorders, paralysis).
* Creatine supplements, corticosteroids, NSAIDS, amino acids, injectible peptides, collagen, and nicotinamide (Vit B3/niacin).
* Presence or history of neurological disorders or significant psychiatric illness.
* Any condition the study investigator believes would interfere with eligibility following the study protocol, effect the study results, or put the subject at undue risk.
* Participation in resistance or aerobic exercise within 48 hours of the test days.
* Participation of \>3 high-intensity exercise sessions per week.
* Undertake recovery methods such as sea swims, foam rolling, cryotherapy or excessive stretching during days 14-17.
* Have been in contact with a suspected or confirmed case of COVID-19 in previous 14 days.
* Are Hepatitis A- or B-positive or have had a sexual partner infected with hepatitis or HIV and not taking medication.
* Are not employed by, or have a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If you are unsure if a company would be considered a competitor to Gatorade, let the study investigator know the name of the other company and the nature of your relationship to that company before ou sign the informed consent
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PepsiCo Global R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kris Osterberg, PhD, RD
Role: PRINCIPAL_INVESTIGATOR
PepsiCo R&D Life Sciences, Sports Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gatorade Sports Science Institute at IMG Academy
Bradenton, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEP-2414
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.